MARKERS FOR PREDICTING OVARIAN CANCER RECURRENCE (Review of literature)
Keywords:
ovarian cancer (OC), cancer antigen (CA 125), human epididymal protein 4 (HE-4), droplet digital polymerase chain reaction (ddPCR), circulating tumor DNA (ctDNA)Abstract
The research literature sources for the last ten years can be found in the PubMed and E-library databases. Combinations of text terms "ovarian neoplasm", "ovarian cancer", "ovarian malignancy", "recurrence" and "ovarian biomarkers" were used to search for studies. Publication reviews on the role of biomarkers in ovarian cancer recurrence were one of the selection criteria for this narrative review. Although several biomarkers of response to various agents in ovarian cancer have been identified in the literature, most lack high-level evidence. This report highlights the unmet need for predictive identification and validation of biomarkers to guide treatment and future trial design in ovarian cancer.
References
Сухарева И.А.,Заурова М.Б., Середа Е.В., ЭнзельД.А., 2021
Yoneda A., Lendorf M.E., Couchman J.R., Multhaupt H.A. Breast and ovarian cancers: A survey and possible roles for the cell surface heparan sulfate proteoglycans. J. Histochem. Cytochem. 2012;60:9–21.
Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424.
Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249.
Zhu X., Lang J. Programmed death-1 pathway blockade produces a synergistic antitumor effect: Combined application in ovarian cancer. J. Gynecol. Oncol. 2017;28:e64.
Maine C.J., Aziz N.H., Chatterjee J., Hayford C., Brewig N., Whilding L., George A.J., Ghaem-Maghami S. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol. Immunother. 2014;63:215–224.
Menon U., Gentry-Maharaj A., Burnell M., Singh N., Ryan A., Karpinskyj C., Carlino G., Taylor J., Massingham S.K., Raikou M., et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. Lancet. 2021;397:2182–2193.
Cho K.R., Shih Ie M. Ovarian cancer. Annu. Rev. Pathol. 2009;4:287–313. doi: 10.1146/annurev.pathol.4.110807.092246.
Openshaw M.R., Fotopoulou C., Blagden S., Gabra H. The next steps in improving the outcomes of advanced ovarian cancer. Womens Health. 2015;11:355–367.
McCloskey C.W., Rodriguez G.M., Galpin K.J.C., Vanderhyden B.C. Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics. Cancers. 2018;10:244.
Nersesian S., Glazebrook H., Toulany J., Grantham S.R., Boudreau J.E. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. Front. Immunol. 2019;10:1782.
Zhang F, Zhang Y, Ke C, et al. Predicting ovarian cancer recurrence by plasma metabolic profiles before and after surgery. Metabolomics 2018;14:65.
Yang WL, Lu Z, Bast RC Jr. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn 2017;17:577-91.
Muinao T, Deka Boruah HP, Pal M. Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells - An updated review. Exp Cell Res 2018;362:1-10.
Sölétormos G, Duffy MJ, Hassan SOA, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European group on tumor markers (EGTM). Int J Gynecol Cancer 2016;26:43-51.
Chatterjee M, Hurley LC, Levin NK, et al. Utility of paraneoplastic antigens as biomarkers for surveillance and prediction of recurrence in ovarian cancer. Cancer Biomark 2017;20:369-387.
Guo N, Peng Z. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study. J Ovarian Res 2017;10:14.
Hiom SC. Diagnosing cancer earlier: reviewing the evidence for improving can- cer survival. Br J Cancer 2015;112:S1-5.
Duraisamy S, Ramasamy S, Kharbanda S, et al. Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16. Gene 2006;373:28-34.
Bast RC, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331–7.
Bast RC, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–7.
Sundar S, Neal RD, Kehoe SJ. Diagnosis of ovarian cancer. BMJ 2015;351:h4443.
Dupont, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 2004;22:3330-9.
Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol 2000;75:264-5.
Colaković S, Lukiç V, Mitroviç L, et al. Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers 2000;15:147-52.
Yang ZJ, Zhao BB, Li L. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer. J Ovarian Res 2016;9:57.
Rustin GJ, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011;21:419-23.
Giuliani M, Gui B, Valentini AL, et al. Early detection of recurrence or progression disease in patients with ovarian cancer after primary debulking surgery. Correlation between CT findings and CA 125 levels. Minerva Ginecol 2017;69:538-47.
Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996;7:361-4.
Low RN, Duggan B, Barone RM, et al. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year. Radiology 2005;235:918-26.
García-Velloso MJ, Jurado M, Ceamanos C, et al. Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma. Eur J Nucl Med Mol Imaging 2007;34:1396-405.
Crawford SM, Peace J. Does the nadir CA125 concentration predict a longterm outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 2005;16:47-50.
Scholler N, Urban N. CA125 in Ovarian Cancer. Biomark Med 2007;1:513-23.
Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010;376:1155-63.
Bast RC Jr. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 2010;116:2850-3.
Verheijen RH, Cibula D, Zola P, et al. Cancer Antigen 125: Lost to Follow-Up?: A European Society of Gynaecological Oncology Consensus Statement. Int J Gynecol Cancer 2012;22:170-4.
Pignata S, Cannella L, Leopardo D, et al. Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. Ann Oncol 2011;22 Suppl 8:i40-4.
Wang PH, Huang YT, Ng KK, et al. Detecting recurrent ovarian cancer: revisit the values of whole-body CT and serum CA 125 levels. Acta Radiol 2019;60:1360-6.
Jing J, Gao Y. Urine biomarkers in the early stages of diseases: current status and perspective. Discov Med 2018;25:57-65.
Grayson K, Gregory E, Khan G, et al. Urine Biomarkers for the Early Detection of Ovarian Cancer - Are We There Yet? Biomark Cancer 2019;11:1179299X19830977.
Lu R, Sun X, Xiao R, et al. Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun 2012;419:274-80.
Azzam AZ, Hashad DI, Kamel NA. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?. Arch Gynecol Obstet 2013;288:167-72.
Plotti F, Guzzo F, Schirò T, et al. Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients. Int J Gynecol Cancer 2019. [Epub ahead of print].
Lakshmanan M, Kumar V, Chaturvedi A, et al. Role of serum HE4 as a prognostic marker in carcinoma of the ovary. Indian J Cancer 2019;56:216-21.
Anastasi E, Marchei GG, Viggiani V, et al. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 2010;31:113-9.
Liao JB, Yip YY, Swisher EM, et al. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates. Gynecol Oncol 2015;137:430-5.
Abbink K, Zusterzeel PL, Geurts-Moespot AJ, et al. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients. Tumour Biol 2018;40:1010428318757103.
Capriglione S, Luvero D, Piotti F, et al. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature. Med Oncol 2017;34:164.
Wang Q, Wu Y, Zhang H, et al. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence. Clin Lab 2019.65.
Plotti F, Capriglione S, Terranova C, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol 2012;33:2117-23.
Havrilesky LJ, Whitehead CM, Rubatt JM, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008;110:374-82. [Crossref] [PubMed]
Granato T, Midulla C, Longo F, et al. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumour Biol 2012;33:1335-9.
Hu ZD, Wei TT, Yang M, et al. Diagnostic value of osteopontin in ovarian cancer: a meta-analysis and systematic review. PLoS One 2015;10:e0126444.
E. Crowley, F. Di Nicolantonio, F. Loupakis, A. Bardelli, Liquid biopsy: monitoring cancer-genetics in the blood, Nat. Rev. Clin. Oncol., 10 (2013), pp. 472-484
G. Siravegna, S. Marsoni, S. Siena, A. Bardelli, Integrating liquid biopsies into the management of cancer, Nat. Rev. Clin. Oncol., 14 (2017), pp. 531-548
P. Mandel, P. Metais, Les acides nucléiques du plasma sanguin chez l’homme, C. R. Seances Soc. Biol. Fil., 142 (1948), pp. 241-243
S.A. Leon, B. Shapiro, D.M. Sklaroff, M.J. Yaros, Free DNA in the serum of cancer patients and the effect of therapy, Cancer Res., 37 (1977), pp. 646-650
Harris FR, Kovtun IV, Smadbeck J, et al. Quantification of somatic chromosomal rearrangements in circulating cell-free DNA from ovarian cancers. Sci Rep. 2016;6:29831.
Parkinson CA, Gale D, Piskorz AM, et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med. 2016;13(12):e1002198.
Barton CA, Hacker NF, Clark SJ, et al. DNA Methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol. 2008;109(1):129-139.
Bondurant AE, Huang Z, Whitaker RS, et al. Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. Gynecol Oncol. 2011;123(3):581-587.
Giannopoulou L, Mastoraki S, Buderath P, et al. ESR1 Methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer. Gynecol Oncol. 2018;150(2):355-360.
Yin C, Luo C, Hu W, et al. Quantitative and qualitative analysis of circulating cell-free DNA can be used as an adjuvant tool for prostate cancer screening: a meta-analysis. Dis Markers. 2016(2016):1-12.
Luo J, Shen L, Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep. 2014;4:6269.
Ai B, Liu H, Huang Y, et al. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer. Oncotarget. 2016;7(28):44583-44595.
Zhang R, Shao F, Wu X, et al. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer. 2010;69(2):225-231.
Cargnin S, Canonico PL, Genazzani AA, et al. Quantitative analysis of circulating cell-free DNA for correlation with lung cancer survival: a systematic review and meta-analysis. J Thorac Oncol. 2017;12(1):43-53.
Fan G, Zhang K, Yang X, et al. Prognostic value of circulating tumor DNA in patients with colon cancer: systematic review. PLoS One. 2017;12(2):e0171991.
Zhou Q, Li W, Leng B, et al. Circulating cell free DNA as the diagnostic marker for ovarian cancer: a systematic review and meta-analysis. PLoS One. 2016;11(6):e0155495.
Ross MG, Russ C, Costello M, Hollinger A, Lennon NJ, Hegarty R, et al. Characterizing and measuring bias in sequence data. Genome Biol. 2013;14:R51.
Huang Y, Xu J, Li K, Wang J, Dai Y, Kang Y. A Novel, Personalized Drug-Screening System for Platinum-Resistant Ovarian Cancer Patients: A Preliminary Clinical Report. Cancer Manag Res. 2021;13:2849–67.
Charo LM, Eskander RN, Okamura R, Patel SP, Nikanjam M, Lanman RB, et al. Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. Mol Oncol. 2021;15:67–79.
Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4:136ra68.
Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1997;37:646–50.
Butler TM, Spellman PT, Gray J. Circulating-tumor DNA as an early detection and diagnostic tool. Curr Opin Genet Dev. 2017;42:14–21.
Zhang L, Liang Y, Li S, Zeng F, Meng Y, Chen Z, et al. The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis. Mol Cancer. 2019;18:36.
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.
Noguchi T, Iwahashi N, Sakai K, Matsuda K, Matsukawa H, Toujima S, et al. Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact. Cancers (Basel). 2020;12:3382.
Wang Y, Li L, Cohen JD, Kinde I, Ptak J, Popoli M, et al. Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. JAMA Oncol. 2019;5:1118–23.
Fiala C, Diamandis EP. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Med. 2018;16:166.
Amant F, Verheecke M, Wlodarska I, Dehaspe L, Brady P, Brison N, et al. Presymptomatic identification of cancers in pregnant women during noninvasive prenatal testing. JAMA Oncol. 2015;1:814–9.
Bianchi DW, Chudova D, Sehnert AJ, Bhatt S, Murray K, Prosen TL, et al. Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies. JAMA. 2015;314:162–9.
Pereira E, Camacho-Vanegas O, Anand S, Sebra R, Catalina Camacho S, Garnar-Wortzel L, et al. Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers. PLoS One. 2015;10:e0145754.
Narayan A, Carriero NJ, Gettinger SN, Kluytenaar J, Kozak KR, Yock TI, et al. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res. 2012;72:3492–8.
Malapelle U, Pisapia P, Sgariglia R, Vigliar E, Biglietto M, Carlomagno C, et al. Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. J Clin Pathol. 2016;69:767–71.
Li S, Huang W, Li Y, Chen B, Li D. A Study of hTERT Promoter Methylation in Circulating Tumour DNAs of Patients with Ovarian Magnificent Tumour. Onco Targets Ther. 2020;13:12317–23.
Giannopoulou L, Mastoraki S, Buderath P, Strati A, Pavlakis K, Kasimir-Bauer S, et al. ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer. Gynecol Oncol. 2018;150:355–60.
Liggett TE, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, et al. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol. 2011;120:113–20.
Ogasawara A, Hihara T, Shintani D, Yabuno A, Ikeda Y, Tai K, et al. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations. Cancer Res Treat. 2020;52:1219–28.
Nemtsova MV, Kalinkin AI, Kuznetsova EB, Bure IV, Alekseeva EA, Bykov II, et al. Clinical relevance of somatic mutations in main driver genes detected in gastric cancer patients by next-generation DNA sequencing. Sci Rep. 2020;10:504.
Bejar R. Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica. 2014;99:956–64.
Harris FR, Kovtun IV, Smadbeck J, Multinu F, Jatoi A, Kosari F, et al. Quantification of somatic chromosomal rearrangements in circulating cell-free DNA from ovarian cancers. Sci Rep. 2016;6:29831.
